Browsing: —-

Attendees at ASCO 2025 conference with a stage presentation on neoadjuvant nivolumab plus chemotherapy in lung cancer, featuring the CheckMate 816 trial update.

Neoadjuvant Nivolumab Plus Chemotherapy in Lung Cancer: CheckMate 816 Update at ASCO 2025

---- 3 Mins Read

Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial…

An official FDA document on a computer screen with the title "Safety Announcement: Importance of DPD Deficiency Discussions Prior to Capecitabine or 5-FU Therapy", emphasizing the need for genetic testing and patient safety in cancer treatment.

FDA Alert Capecitabine & The Critical Role of DPD Deficiency Testing Before Treatment

---- 2 Mins Read

The U.S. Food and Drug Administration (FDA) has recently underscored the significance of understanding Dihydropyrimidine Dehydrogenase (DPD) deficiency in patients…

TEPMETKO (tepotinib) FDA Where is tepotinib approved? [VIDEO]

---- 6 Mins Read

On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in…

How can ctDNA testing inform patient care?

---- 1 Min Read

How can MRD testing inform patient care?

---- 1 Min Read

Chief Nerd – NEW – Pfizer CEO Albert Bourla Says Their â€˜New Moonshotâ€™ is Cancer â€œItâ€™s all about oncology. Disproportionately we are investing capital and disproportionately reorg…

---- 1 Min Read

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

---- 1 Min Read

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →

ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →

PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →

Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →

News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →

News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →

Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →

Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →

Browsing: —-

Neoadjuvant Nivolumab Plus Chemotherapy in Lung Cancer: CheckMate 816 Update at ASCO 2025

FDA Alert Capecitabine & The Critical Role of DPD Deficiency Testing Before Treatment

TEPMETKO (tepotinib) FDA Where is tepotinib approved? [VIDEO]

How can ctDNA testing inform patient care?

How can MRD testing inform patient care?

659ae0d8c00e2

Chief Nerd – NEW – Pfizer CEO Albert Bourla Says Their â€˜New Moonshotâ€™ is Cancer â€œItâ€™s all about oncology. Disproportionately we are investing capital and disproportionately reorg…

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

6446cee6a24f9